Cargando…

Involvement of P-gp on Reversing Multidrug Resistance Effects of 23-Hydroxybetulinic Acid on Chemotherapeutic Agents

Betulinic acid (BA) and 23-Hydroxybetulinic acid (23-HBA) are natural products with similar structures, which show a range of biological effects including cytotoxicity activity. The aim of current research was to investigate and evaluate the combinational cytotoxicity of BA and 23-HBA with chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhihao, Wen, Xiaozhou, Wang, Guangji, Zhou, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714961/
https://www.ncbi.nlm.nih.gov/pubmed/34975494
http://dx.doi.org/10.3389/fphar.2021.796745
_version_ 1784624043059576832
author Liu, Zhihao
Wen, Xiaozhou
Wang, Guangji
Zhou, Ying
author_facet Liu, Zhihao
Wen, Xiaozhou
Wang, Guangji
Zhou, Ying
author_sort Liu, Zhihao
collection PubMed
description Betulinic acid (BA) and 23-Hydroxybetulinic acid (23-HBA) are natural products with similar structures, which show a range of biological effects including cytotoxicity activity. The aim of current research was to investigate and evaluate the combinational cytotoxicity of BA and 23-HBA with chemotherapeutic agents in vitro, and to clarify the potential interaction and related mechanism with P-gp. Instead of BA, 23-HBA could increase cytotoxicity of MCF-7/ADR cells to adriamaycin (ADR) and vincristine (VCR). The intracellular accumulation of ADR/VCR in MCF-7/ADR cells was obviously increased in the presence of 23-HBA. Furthermore, 23-HBA could show dose-dependent increase on the transport of VCR and digoxin, which are typical P-gp substrates, in both MDCK-MDR1 and Caco-2 cells. However, the transport of BA and 23-HBA was not influenced by P-gp inhibition in MDCK-MDR1 cells. MDR1 shift assay and molecular docking model suggested that both compounds showed interaction with P-gp, yet the binding affinity and sites are different. In conclusion, 23-HBA could strongly improve the efficacy of anti-tumor agents in multidrug resistance (MDR) cells, which was related to P-gp inhibition. The MDR1 shift assay and molecular docking study further revealed that 23-HBA and BA showed different interaction modes with P-gp.
format Online
Article
Text
id pubmed-8714961
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87149612021-12-30 Involvement of P-gp on Reversing Multidrug Resistance Effects of 23-Hydroxybetulinic Acid on Chemotherapeutic Agents Liu, Zhihao Wen, Xiaozhou Wang, Guangji Zhou, Ying Front Pharmacol Pharmacology Betulinic acid (BA) and 23-Hydroxybetulinic acid (23-HBA) are natural products with similar structures, which show a range of biological effects including cytotoxicity activity. The aim of current research was to investigate and evaluate the combinational cytotoxicity of BA and 23-HBA with chemotherapeutic agents in vitro, and to clarify the potential interaction and related mechanism with P-gp. Instead of BA, 23-HBA could increase cytotoxicity of MCF-7/ADR cells to adriamaycin (ADR) and vincristine (VCR). The intracellular accumulation of ADR/VCR in MCF-7/ADR cells was obviously increased in the presence of 23-HBA. Furthermore, 23-HBA could show dose-dependent increase on the transport of VCR and digoxin, which are typical P-gp substrates, in both MDCK-MDR1 and Caco-2 cells. However, the transport of BA and 23-HBA was not influenced by P-gp inhibition in MDCK-MDR1 cells. MDR1 shift assay and molecular docking model suggested that both compounds showed interaction with P-gp, yet the binding affinity and sites are different. In conclusion, 23-HBA could strongly improve the efficacy of anti-tumor agents in multidrug resistance (MDR) cells, which was related to P-gp inhibition. The MDR1 shift assay and molecular docking study further revealed that 23-HBA and BA showed different interaction modes with P-gp. Frontiers Media S.A. 2021-12-15 /pmc/articles/PMC8714961/ /pubmed/34975494 http://dx.doi.org/10.3389/fphar.2021.796745 Text en Copyright © 2021 Liu, Wen, Wang and Zhou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Liu, Zhihao
Wen, Xiaozhou
Wang, Guangji
Zhou, Ying
Involvement of P-gp on Reversing Multidrug Resistance Effects of 23-Hydroxybetulinic Acid on Chemotherapeutic Agents
title Involvement of P-gp on Reversing Multidrug Resistance Effects of 23-Hydroxybetulinic Acid on Chemotherapeutic Agents
title_full Involvement of P-gp on Reversing Multidrug Resistance Effects of 23-Hydroxybetulinic Acid on Chemotherapeutic Agents
title_fullStr Involvement of P-gp on Reversing Multidrug Resistance Effects of 23-Hydroxybetulinic Acid on Chemotherapeutic Agents
title_full_unstemmed Involvement of P-gp on Reversing Multidrug Resistance Effects of 23-Hydroxybetulinic Acid on Chemotherapeutic Agents
title_short Involvement of P-gp on Reversing Multidrug Resistance Effects of 23-Hydroxybetulinic Acid on Chemotherapeutic Agents
title_sort involvement of p-gp on reversing multidrug resistance effects of 23-hydroxybetulinic acid on chemotherapeutic agents
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714961/
https://www.ncbi.nlm.nih.gov/pubmed/34975494
http://dx.doi.org/10.3389/fphar.2021.796745
work_keys_str_mv AT liuzhihao involvementofpgponreversingmultidrugresistanceeffectsof23hydroxybetulinicacidonchemotherapeuticagents
AT wenxiaozhou involvementofpgponreversingmultidrugresistanceeffectsof23hydroxybetulinicacidonchemotherapeuticagents
AT wangguangji involvementofpgponreversingmultidrugresistanceeffectsof23hydroxybetulinicacidonchemotherapeuticagents
AT zhouying involvementofpgponreversingmultidrugresistanceeffectsof23hydroxybetulinicacidonchemotherapeuticagents